The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and
As per the agreement terms, Pfizer will tap into the de-identified, real-world datasets and analytical expertise from Flatiron Health to chalk out development strategies and activities for various
Results from the study will be presented at the MDS International Congress in Nice, France, September 22-26, 2019 as poster #13705 and poster #13711. ENGAGE is the first
The mid-stage trial met the primary endpoint by recording a statistically significant improvement from baseline in motor symptoms in patients treated with tavapadon in comparison with those in
The opinion was based on positive findings from the Phase III JAVELIN Renal 101 study, which demonstrated a significant extension in median progression-free survival (PFS) and a clinically
The partnership will see compounds from the retinal disease pipeline portfolio of Boehringer Ingelheim combined with the intravitreal (IVT) drug delivery technologies of Inflammasome. Inflammasome’s technology will be
LINZESS was approved by the National Medical Products Administration for adults with IBS-C in China in January 2019. LINZESS is expected to be launched in China in the
The PREVENT trial is assessing the efficacy and safety of Cosentyx compared to placebo with the primary endpoint being ASAS40 at Week 16. All the secondary endpoints of
Topline data from this dose regimen trial is expected in the first half of 2020. “We are extremely grateful to the patients who volunteer to participate in our
The primary endpoint is the change from baseline in the 6-minute walk test (6-MWT) at 12 months. Secondary endpoints will evaluate the efficacy of patisiran on quality of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.